Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Apr;39(4):e14769.
doi: 10.1111/dme.14769. Epub 2022 Jan 26.

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

Janaka Karalliedde  1 , Peter Winocour  2 , Tahseen A Chowdhury  3 , Parijat De  4 , Andrew H Frankel  5 , Rosa M Montero  6 , Ana Pokrajac  7 , Debasish Banerjee  8 , Indranil Dasgupta  9 , Damian Fogarty  10 , Adnan Sharif  11 , Mona Wahba  12 , Patrick B Mark  13 , Sagen Zac-Varghese  14 , Dipesh C Patel  15   16 , Stephen C Bain  17
Affiliations
Practice Guideline

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

Janaka Karalliedde et al. Diabet Med. 2022 Apr.

Abstract

A significant percentage of people with diabetes develop chronic kidney disease and diabetes is also a leading cause of end-stage kidney disease (ESKD). The term diabetic kidney disease (DKD) includes both diabetic nephropathy (DN) and diabetes mellitus and chronic kidney disease (DM CKD). DKD is associated with high morbidity and mortality, which are predominantly related to cardiovascular disease. Hyperglycaemia is a modifiable risk factor for cardiovascular complications and progression of DKD. Recent clinical trials of people with DKD have demonstrated improvement in clinical outcomes with sodium glucose co-transporter-2 (SGLT-2) inhibitors. SGLT-2 inhibitors have significantly reduced progression of DKD and onset of ESKD and these reno-protective effects are independent of glucose lowering. At the time of this update Canagliflozin and Dapagliflozin have been approved for delaying the progression of DKD. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have undertaken a literature review and critical appraisal of the available evidence to inform clinical practice guidelines for management of hyperglycaemia in adults with DKD. This 2021 guidance is for the variety of clinicians who treat people with DKD, including GPs and specialists in diabetes, cardiology and nephrology.

PubMed Disclaimer

References

REFERENCES

    1. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.
    1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.
    1. de Boer IH and f.t.D.E.R. Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):24-30.
    1. Lind M, Svensson A-M, Kosiborod M, et al. Glycemic control and excess mortality in Type 1 diabetes. N Engl J Med. 2014;371(21):1972-1982.
    1. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in Type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2012;172(10).

Publication types

Substances